What's Going On Pfizer's Subsidiary Biohaven Stock?
Portfolio Pulse from Vandana Singh
Pfizer's subsidiary Biohaven released an updated investor presentation with additional data on its BHV-1300 program, a potential competitor to FcRn-targeting therapeutics. The data shows that BHV-1300 takes a direct approach by targeting IgG itself for degradation, which sets it apart from competitors. Biohaven's data shows a substantial reduction in IgG levels of over 90% based on experiments conducted on nonhuman primates. Biohaven's shares are up 27% at $22.42.
September 27, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biohaven's BHV-1300 program could potentially compete with argenx's Vyvgart.
Biohaven's BHV-1300 program could potentially compete with argenx's Vyvgart, which could negatively impact argenx's stock.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Biohaven's BHV-1300 program could potentially compete with Immunovant's IMVT-1402.
Biohaven's BHV-1300 program could potentially compete with Immunovant's IMVT-1402, which could negatively impact Immunovant's stock.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Biohaven's BHV-1300 program could potentially compete with Janssen's nipocalimab.
Biohaven's BHV-1300 program could potentially compete with Janssen's nipocalimab, which could negatively impact Janssen's stock.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Biohaven's shares are up 27% following the release of promising data on its BHV-1300 program.
The promising data on Biohaven's BHV-1300 program has led to a surge in its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Pfizer's subsidiary Biohaven's promising data on its BHV-1300 program could potentially boost Pfizer's stock.
As Pfizer owns Biohaven, the promising data from Biohaven's BHV-1300 program could potentially boost Pfizer's stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80